All inspectors · Key sources (PDF) · STEMI shock sheet (PDF)
The STEMI with cardiogenic shock one-pagerOpen it in a new tab

The patient in front of you

Mr. R., 64, arrives with an anterior STEMI and is already in shock: systolic pressure in the 80s on norepinephrine, lactate rising, ejection fraction about 25% on echo. He is awake and following commands, and he is on the cath-lab table for emergency PCI. Suppose Mr. R. had collapsed at home and been resuscitated, now with a pulse and stable blood pressure, and no ST elevation or new bundle-branch block.

This page helps you decide: Does a second trial change the answer about immediate angiography in that case?

After this page you can

Your routine for every trial

Work through the six steps in order. Each question at the end belongs to one step, and the answer is on that step's page.

  1. Who was studied? Which patients could enter, which could not, and how sick were they?
  2. Compared with what? What did one group get that the other did not, and what was measured?
  3. What was the main result? Both percentages, the effect size with its 95% CI, and the number needed to treat (and to harm).
  4. Any design traps? Blinding, the choice of endpoint, how close the CI comes to no effect, how long it took, who paid.
  5. Does it apply to my patient? Would my patient have been allowed into the trial?
  6. What did it change? What the guideline now says, and what the trial does not tell you.

Take-home

Mr. R.'s STEMI with shock keeps him on the emergency-revascularization path; TOMAHAWK excluded ST elevation and instability, so it says nothing about him. Had he instead been resuscitated at home (stable, no ST elevation, no new bundle-branch block), TOMAHAWK would apply: it agrees with COACT and leans further, with no benefit from immediate angiography (30-day death 54.0% vs 46.0%), so intensive care first and angiography when a coronary cause remains likely. On the one-pager it sits on page 2, in the “Cardiac arrest + STEMI” box (the COACT / TOMAHAWK row).